Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue remains negative
Q1 FY2026 deferred revenue was $0, compared with $0 a year earlier.
Context
- Deferred revenue amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Deferred revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Deferred Revenue vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 deferred revenue of $0 is the 5th highest of the 11 companies compared; the peer median is $0.
- Deferred revenue amounts to 0.0% of total assets for AARD, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $52.3M | +1.2% | +9.6% | 23.5% | |
| Mar 2026 | $29.08M | -28.8% | — | 12.3% | |
| Mar 2026 | $5.72M | — | — | 4.2% | |
| Mar 2026 | $994K | -64.9% | -42.4% | 0.7% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AARD) | $0 | -28.8% | -16.4% | 0.0% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.